NBTX

Nanobiotix S.A.

Price Chart

Latest Quote

$37.79

+0.26 (+0.69%)

Current Price

Previous Close	$37.53
Open	$36.16
Day High	$38.38
Day Low	$36.12
Volume	218,422

Fetched: 2026-07-18T01:10:02

Stock Information

Note: Financial values converted from EUR to USD

Shares Outstanding	50.79M
Total Debt	$109.10M
Cash Equivalents	$60.38M
Revenue	$37.30M
Net Income	$-27.42M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.92B
EPS (TTM)	$-0.57
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.87B
Sales	$37.30M
Income	$-27.42M
Book/sh	$-2.00
Cash/sh	$1.04
Employees	100

Financial Ratios

Quick Ratio	1.05
Current Ratio	1.09

Returns & Margins

ROA	-10.06%
Gross Margin	100.00%
Operating Margin	-196.42%
Profit Margin	-73.52%

Ownership

Institutional Ownership	11.76%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	487.26
P/S	58.88
P/B	-18.87

Analyst Data

Recommendation	none
Target Price	$43.64

Technical Indicators

SMA20	$37.91
SMA50	$39.94
SMA200	$29.01
RSI	54.82
ATR	2.6809

Shares Float	31.82M
Short Float	0.14%
Short Ratio	0.69
Volatility	0.56
Rel Volume	2.03

Performance History

Week	-5.69%
Month	+5.00%
Quarter	+16.42%
6 Months	+75.52%
YTD	+70.76%
Year	+623.53%
3 Years	+523.60%
5 Years	+160.98%
10 Years	+122.56%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$37.79	218,422
2026-07-16	$37.53	144,600
2026-07-15	$39.96	104,600
2026-07-14	$41.64	73,600
2026-07-13	$39.15	107,000
2026-07-10	$40.07	119,900
2026-07-09	$38.95	39,000
2026-07-08	$38.80	62,100
2026-07-07	$38.80	108,300
2026-07-06	$41.10	264,200
2026-07-02	$38.40	94,500
2026-07-01	$39.48	77,300
2026-06-30	$37.70	99,600
2026-06-29	$35.96	109,600
2026-06-26	$35.99	112,000
2026-06-25	$34.43	55,600
2026-06-24	$34.35	89,200
2026-06-23	$36.60	124,500
2026-06-22	$35.23	97,100
2026-06-18	$36.27	49,600

About Nanobiotix S.A.

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

📰 Latest News

Nanobiotix (NBTX) Provides Update on Operational Progress

Insider Monkey • 2026-06-22T12:47:31Z

Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally

Simply Wall St. • 2026-05-30T22:04:06Z

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Uncertainty Surrounding US-Iran Talks

MT Newswires • 2026-05-21T13:18:35Z

How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer

Investor's Business Daily • 2026-05-20T12:00:49Z

Assessing Nanobiotix (ENXTPA:NANO) Valuation After Strong Recent Share Price Momentum

Simply Wall St. • 2026-04-27T11:08:21Z

Nanobiotix H2 Earnings Call Highlights

MarketBeat • 2026-04-01T15:20:17Z

Sector Update: Health Care Stocks Gain Late Afternoon

MT Newswires • 2026-03-25T19:49:48Z

Nanobiotix (ENXTPA:NANO): Assessing Valuation After a Powerful Multi‑Month Share Price Surge

Simply Wall St. • 2025-12-08T07:06:19Z

Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue

Motley Fool • 2025-11-24T15:29:00Z

Nanobiotix (ENXTPA:NANO): Evaluating Valuation After $71 Million Royalty Deal Expands Growth Prospects

Simply Wall St. • 2025-11-13T16:09:42Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$33,862,233	$-13,262,508	$34,336,302	$0
Operating Revenue	$25,910,440	$-20,029,700	$33,984,463	$0
Expenses
Interest Expense	$11,874,571	$9,236,920	$9,118,117	$6,667,809
Total Expenses	$46,220,012	$64,864,060	$64,925,746	$53,350,467
Other Income Expense	$-3,694,311	$3,409,870	$-7,221,841	$2,405,757
Net Non Operating Interest Income Expense	$-11,315,970	$-2,998,629	$-7,402,330	$-14,206,077
Total Other Finance Cost	$566,598	$-3,235,092	$-325,565	$7,830,706
Interest Expense Non Operating	$11,874,571	$9,236,920	$9,118,117	$6,667,809
Operating Expense	$46,220,012	$64,864,060	$64,925,746	$53,350,467
Other Operating Expenses	$-461,503	$-956,134	$511,766	$391,821
General And Administrative Expense	$23,100,296	$22,914,096	$24,744,116	$19,968,014
Rent Expense Supplemental	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-27,371,487	$-77,829,561	$-45,350,696	$-65,159,925
Net Interest Income	$-11,315,970	$-2,998,629	$-7,402,330	$-14,206,077
Interest Income	$1,125,200	$3,003,198	$1,390,222	$292,438
Normalized Income	$-24,600,753	$-80,386,964	$-39,934,315	$-66,964,243
Net Income From Continuing And Discontinued Operation	$-27,371,487	$-77,829,561	$-45,350,696	$-65,159,925
Total Operating Income As Reported	$2,389,765	$-78,126,568	$-30,590,586	$-53,349,324
Net Income Common Stockholders	$-27,371,487	$-77,829,561	$-45,350,696	$-65,159,925
Net Income	$-27,371,487	$-77,829,561	$-45,350,696	$-65,159,925
Net Income Including Noncontrolling Interests	$-27,371,487	$-77,830,704	$-45,350,696	$-65,162,210
Net Income Continuous Operations	$-27,371,487	$-77,830,704	$-45,350,696	$-65,162,210
Pretax Income	$-27,368,060	$-77,715,328	$-45,213,615	$-65,150,786
Interest Income Non Operating	$1,125,200	$3,003,198	$1,390,222	$292,438
Operating Income	$-12,357,779	$-78,126,568	$-30,589,444	$-53,350,467
Depreciation Amortization Depletion Income Statement	$394,106	$364,405	$308,430	$382,682
Depreciation And Amortization In Income Statement	$394,106	$364,405	$308,430	$382,682
Amortization Of Intangibles Income Statement	$1,142	$1,142	$0	$1,142
Depreciation Income Statement	$392,963	$363,262	$308,430	$381,540
Special Income Charges	-	-	$0	$0
Per Share
Diluted EPS	$-0.57	$-1.64	$-1.23	$-1.87
Basic EPS	$-0.57	$-1.64	$-1.23	$-1.87
Other
Tax Effect Of Unusual Items	$-923,578	$852,467	$-1,805,460	$601,439
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-10,091,387	$-70,036,553	$-27,145,304	$-59,175,232
Total Unusual Items	$-3,694,311	$3,409,870	$-7,221,841	$2,405,757
Total Unusual Items Excluding Goodwill	$-3,694,311	$3,409,870	$-7,221,841	$2,405,757
Reconciled Depreciation	$1,707,791	$1,851,725	$1,728,353	$1,713,502
EBITDA (Bullshit earnings)	$-13,785,698	$-66,626,683	$-34,367,145	$-56,769,475
EBIT	$-15,493,488	$-68,478,408	$-36,095,498	$-58,482,978
Diluted Average Shares	$54,626,029	$53,992,675	$42,184,327	$39,731,662
Basic Average Shares	$54,626,029	$53,992,675	$42,184,327	$39,731,662
Diluted NI Availto Com Stockholders	$-27,371,487	$-77,829,561	$-45,350,696	$-65,159,925
Tax Provision	$3,427	$115,376	$137,080	$11,423
Gain On Sale Of Security	$-3,694,311	$3,409,870	$-7,221,841	$2,405,757
Other Taxes	$-3,217,957	$-3,769,705	$-4,499,657	$-4,673,292
Amortization	$1,142	$1,142	$0	$1,142
Research And Development	$26,405,071	$46,311,399	$43,861,091	$37,281,242
Selling General And Administration	$23,100,296	$22,914,096	$24,744,116	$19,968,014
Other Gand A	$9,134,110	$9,222,070	$11,296,550	$8,901,074
Salaries And Wages	$13,966,186	$13,692,026	$13,447,566	$11,066,941
Rent And Landing Fees	-	-	-	-

Fetched: 2026-07-15

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-96,519,303	$-75,062,826	$-2,115,604	$-30,895,590
Total Assets	$77,404,613	$77,013,934	$107,261,820	$68,276,215
Total Non Current Assets	$5,723,098	$6,798,035	$7,491,432	$8,466,986
Other Non Current Assets	$28,558	-	-	-
Non Current Prepaid Assets	$467,215	$463,788	$341,558	$332,419
Goodwill And Other Intangible Assets	$11,423	$7,996	$9,139	$1,142
Other Intangible Assets	$11,423	$7,996	$9,139	$1,142
Current Assets	$71,681,515	$70,214,757	$99,770,388	$59,810,371
Other Current Assets	$2,285	$-1,142	$1,142	$1,142
Prepaid Assets	$2,647,932	$3,649,760	$2,924,377	$3,405,300
Receivables	$8,773,132	$9,749,828	$10,846,470	$9,124,971
Other Receivables	$1,628,970	$1,239,433	$3,975,325	$3,131,140
Taxes Receivable	$4,704,135	$5,109,664	$5,837,331	$5,878,455
Accounts Receivable	$2,440,027	$3,400,731	$1,033,813	$115,376
Cash Cash Equivalents And Short Term Investments	$60,258,166	$56,816,311	$85,998,398	$47,278,957
Cash And Cash Equivalents	$60,258,166	$56,816,311	$85,998,398	$47,278,957
Cash Equivalents	$59,332,875	$50,750,513	$0	$3,213,388
Cash Financial	$925,291	$6,064,656	$85,998,398	$44,066,711
Investmentin Financial Assets	-	-	$0	$0
Debt
Net Debt	$45,087,959	-	-	$7,139,593
Total Debt	$108,886,220	$58,147,131	$57,762,164	$60,735,662
Long Term Debt And Capital Lease Obligation	$103,963,899	$52,522,274	$52,025,358	$55,526,615
Long Term Debt	$101,806,029	$49,130,682	$47,589,672	$50,308,429
Current Debt And Capital Lease Obligation	$4,922,321	$5,624,857	$5,736,806	$5,209,047
Current Debt	$3,540,096	$4,184,373	$4,367,146	$4,110,121
Other Current Borrowings	$3,540,096	$4,184,373	$4,367,146	$4,110,121
Liabilities
Total Liabilities Net Minority Interest	$173,912,492	$152,068,764	$109,368,286	$99,170,662
Total Non Current Liabilities Net Minority Interest	$108,220,239	$84,745,257	$52,396,617	$55,835,045
Other Non Current Liabilities	$3,677,176	$31,729,494	$2,285	-
Current Liabilities	$65,692,253	$67,323,507	$56,971,668	$43,335,617
Other Current Liabilities	$356,408	$8,950,194	-	-
Current Deferred Liabilities	$41,371,943	$20,745,944	$20,822,481	$18,931,916
Payables And Accrued Expenses	$18,906,785	$31,502,170	$29,544,208	$18,821,110
Payables	$16,004,112	$13,738,862	$16,557,002	$12,659,355
Other Payable	$700,251	$767,649	$479,781	$557,459
Total Tax Payable	$7,787,297	$7,848,983	$8,429,289	$7,533,699
Accounts Payable	$7,516,564	$5,122,230	$7,647,932	$4,568,197
Equity
Common Stock Equity	$-96,507,879	$-75,054,830	$-2,106,466	$-30,894,447
Total Equity Gross Minority Interest	$-96,507,879	$-75,054,830	$-2,106,466	$-30,894,447
Stockholders Equity	$-96,507,879	$-75,054,830	$-2,106,466	$-30,894,447
Gains Losses Not Affecting Retained Earnings	$-429,683,561	$-355,847,602	$-315,366,681	$-258,832,526
Other Equity Adjustments	$-429,683,561	$-355,847,602	$-315,366,681	$-258,832,526
Retained Earnings	$-27,371,487	$-77,829,561	$-45,350,696	$-65,159,925
Other
Treasury Shares Number	$25,266	$25,266	$25,266	$25,266
Ordinary Shares Number	$55,275,244	$54,152,081	$53,816,779	$39,814,660
Share Issued	$55,300,510	$54,177,347	$53,842,046	$39,839,926
Tangible Book Value	$-96,519,303	$-75,062,826	$-2,115,604	$-30,895,590
Invested Capital	$8,838,245	$-21,739,775	$49,850,353	$23,524,103
Working Capital	$5,989,262	$2,891,250	$42,798,719	$16,474,754
Capital Lease Obligations	$3,540,096	$4,832,077	$5,805,346	$6,317,112
Total Capitalization	$5,298,149	$-25,924,148	$45,483,206	$19,413,982
Treasury Stock	$260,452	$260,452	$260,452	$260,452
Additional Paid In Capital	$359,148,950	$357,257,244	$357,256,101	$292,163,574
Capital Stock	$1,658,670	$1,625,543	$1,615,262	$1,194,882
Common Stock	$1,658,670	$1,625,543	$1,615,262	$1,194,882
Employee Benefits	$579,164	$493,489	$368,974	$308,430
Non Current Pension And Other Postretirement Benefit Plans	$579,164	$493,489	$368,974	$308,430
Long Term Capital Lease Obligation	$2,157,871	$3,391,592	$4,435,686	$5,218,186
Current Deferred Revenue	$41,371,943	$20,745,944	$20,822,481	$18,931,916
Current Capital Lease Obligation	$1,382,225	$1,440,484	$1,369,660	$1,098,926
Current Provisions	$134,796	$500,343	$868,175	$373,544
Current Accrued Expenses	$2,902,673	$17,763,308	$12,987,205	$6,161,754
Net PPE	$5,215,901	$6,326,251	$7,140,735	$8,133,424
Accumulated Depreciation	$-14,211,788	$-12,589,673	$-10,807,630	$-9,344,299
Gross PPE	$19,427,690	$18,915,924	$17,948,366	$17,477,724
Construction In Progress	$732,237	$446,653	$214,759	$392,963
Other Properties	$2,957,505	$2,848,983	$2,659,356	$2,429,746
Machinery Furniture Equipment	$5,380,397	$5,309,573	$5,023,989	$4,987,434
Buildings And Improvements	$10,357,551	$10,310,715	$10,050,262	$9,666,438
Properties	$0	$0	$0	$0
Investments And Advances	-	-	$0	$0
Available For Sale Securities	-	-	-	-

Fetched: 2026-07-15

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-38,802,832	$-23,302,490	$-14,636,737	$-42,490,289
Operating Activities
Operating Cash Flow	$-38,179,117	$-22,333,790	$-14,251,770	$-42,384,052
Cash Flow From Continuing Operating Activities	$-38,177,975	$-22,333,790	$-14,252,913	$-42,386,336
Operating Gains Losses	$174,777	$-3,427	$-27,416	$3,427
Investing Activities
Capital Expenditure	$-623,715	$-968,700	$-384,967	$-106,237
Investing Cash Flow	$-660,270	$-1,090,930	$-398,675	$157,642
Cash Flow From Continuing Investing Activities	$-660,270	$-1,090,930	$-398,675	$156,500
Net Other Investing Changes	-	-	-	$1,142
Financing Activities
Issuance Of Capital Stock	$1,753,484	$0	$68,716,014	$0
Financing Cash Flow	$42,741,603	$-5,865,890	$53,428,146	$-6,455,335
Cash Flow From Continuing Financing Activities	$42,742,745	$-5,865,890	$53,428,146	$-6,454,192
Net Other Financing Charges	$-888,737	-	$-3,187,114	$-1,142
Cash Dividends Paid	$0	$0	$0	$0
Net Common Stock Issuance	$1,753,484	$0	$68,716,014	$0
Common Stock Issuance	$1,753,484	$0	$68,716,014	$0
Other
Repayment Of Debt	$-5,419,237	$-4,746,402	$-4,300,891	$-5,408,956
Issuance Of Debt	$49,043,864	$0	$171,350	$0
End Cash Position	$60,258,166	$56,816,311	$85,998,398	$47,278,957
Beginning Cash Position	$56,816,311	$85,998,398	$47,278,957	$95,865,887
Effect Of Exchange Rate Changes	$-459,219	$107,379	$-58,259	$94,814
Changes In Cash	$3,901,074	$-29,289,467	$38,777,701	$-48,681,744
Interest Paid Cff	$-1,747,772	$-1,119,488	$-7,971,213	$-1,045,236
Net Issuance Payments Of Debt	$43,624,627	$-4,746,402	$-4,129,541	$-5,408,956
Net Long Term Debt Issuance	$43,624,627	$-4,746,402	$-4,129,541	$-5,408,956
Long Term Debt Payments	$-5,419,237	$-4,746,402	$-4,300,891	$-5,408,956
Long Term Debt Issuance	$49,043,864	$0	$171,350	$0
Net Investment Purchase And Sale	$-36,555	$-122,230	$-13,708	$262,737
Net Intangibles Purchase And Sale	$-9,139	$-2,285	$-10,281	$-1,142
Purchase Of Intangibles	$-9,139	$-2,285	$-10,281	$-1,142
Net PPE Purchase And Sale	$-614,576	$-966,415	$-374,686	$-105,095
Purchase Of PPE	$-614,576	$-966,415	$-374,686	$-105,095
Taxes Refund Paid	$-226,182	$-70,825	$-7,996	$0
Change In Working Capital	$-3,885,081	$16,315,969	$11,331,962	$2,626,228
Change In Other Working Capital	$-18,277	$13,928,489	$1,841,444	-
Change In Other Current Liabilities	$199,909	$-255,883	$825,908	$1,393,649
Change In Payables And Accrued Expense	$-6,181,174	$2,237,834	$9,909,755	$3,318,483
Change In Payable	$-6,181,174	$2,237,834	$9,909,755	$3,318,483
Change In Receivables	$2,114,462	$405,529	$-1,245,145	$-2,085,904
Changes In Account Receivables	$959,561	$-2,364,633	$-920,722	$-115,376
Other Non Cash Items	$-12,368,060	$32,677,632	$13,678,318	$14,458,533
Stock Based Compensation	$4,042,723	$4,909,755	$3,680,603	$3,625,771
Provisionand Write Offof Assets	$-257,025	$-300,434	$578,021	$348,412
Deferred Tax	$3,427	$115,376	$137,080	$0
Deferred Income Tax	$3,427	$115,376	$137,080	$0
Depreciation Amortization Depletion	$1,707,791	$1,851,725	$1,728,353	$1,713,502
Depreciation And Amortization	$1,707,791	$1,851,725	$1,728,353	$1,713,502
Net Income From Continuing Operations	$-27,371,487	$-77,829,561	$-45,350,696	$-65,159,925
Proceeds From Stock Option Exercised	-	-	$0	$0
Purchase Of Investment	-	-	-	-

Fetched: 2026-07-15